Erlotinib MUPs / Granules
Erlotinib MUPs / Granules
Erlotinib granules/MUPs developed to overcome poor bioavailability due to poor solubility, and to reduce toxicity through matrix-based encapsulation. Ready-for-compression granules at 50% w/w strength suitable for tablet manufacture.
- Complete technical package available for registrations in all regulated/semi-regulated markets.
- Products protected by ongoing patents are not offered.
Additional Information
| Percentage | 50% |
|---|---|
| Target Formulations | Tablets |
